Navigation Links
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Date:8/28/2007

ss than $35 million, compared to original guidance estimates of approximately $40 million. Sunesis expects its 2008 cash used in operating activities to be at or below its 2007 level.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the safety and potential efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the anticipated timing of the commencement and completion of clinical trials and the announcement of clinical results, whether any future trial will constitute a registration trial sufficient to support an application for regulatory approval, potential corporate partnerships or collaborations, plans to strategically invest in drug discovery efforts, ability to advance high-quality lead candidates into preclinical and clinical development, the estimated reduction in Sunesis' operating expenses, the estimated restructuring charges to be incurred in the third quarter, and Sunesis' ongoing cash requirements . Words such as "anticipates," "plans," "will," "optimistic," "is expected" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ,60s cleanup of toxic pollution in Seattle,s ... Lake Washington, ... but sometimes, at least in the case of a little fish called ... study led by researchers at Fred Hutchinson Cancer Research,Center and published online ...
... KV is Now Offering The Complete Line of All Four ... ... the 50 mg ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires ...
... BALTIMORE, May 15 Lentigen Corporation announced today,that ... (NIH) small,business innovation research (SBIR) grants to collaborate ... its proprietary,lentiviral vector (LV) technology to the development ... medical need:, -- Melanoma, with Michael ...
Cached Biology Technology:Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 2Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 3Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 4KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 2KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 3KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 4Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2
(Date:4/20/2014)... gene expression analysis growing in importance for both ... Mellon University and the University of Maryland have ... up estimates of gene activity from RNA sequencing ... after the famously speedy fish, estimates of gene ... completed in a few minutes, with accuracy that ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may ... to be more careful. In the wild, a plant whose ... would risk disaster. More than just an insurance policy against ... seed dormancy has long-term advantages too: Plants whose seeds ... to more species, finds in a team of researchers working ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2
... confuse the immune system and thwarting biological defenses. ... neutralize the cancer,s chemical arsenal and boost a patient,s ... time are rarely successful. Now, researchers have developed ... of both an immune-system booster and a chemical to ...
... A new genetic mutation that causes familial amyotrophic lateral ... Lou Gehrig,s Disease, has been identified by a team ... Massachusetts Medical School (UMMS). Mutations to the profilin (PFN1) ... of nerve cell axons, is estimated to account for ...
... times more valuable while improving ecology, according to a ... the online journal PLoS ONE . By ... harmful government subsidies, and putting in place effective management ... year, rather than losing US$13 billion per year. ...
Cached Biology News:Elegant delivery 2Elegant delivery 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
Procollagen type I C-terminal propeptide (human, PICP)...
... Small Molecule Localization in Early Drug ... Get essential drug compound localization ... spectrometry. Protein Discoverys imaging mass spectrometry service ... them with histological images so you can ...
Biology Products: